Another TLR7/8 agonist-based nanovaccine combined with sunitinib and PD-L1 antibody treatment was proven to upregulate activation of CD8+ T cells and reduce MDSCs and PD-L1high M2 macrophages in the tumor, leading to enhanced antitumor efficacy in B16F10 and MB49 mice models [160]. This evidence concerns the gene TLR7 and neoplasm.